Can I read iGlarLixi vs IDegAsp in Type 2 Diabetes on EtoBox?

iGlarLixi vs IDegAsp in Type 2 Diabetes by pınar güven is a document available to read on EtoBox.

What is iGlarLixi vs IDegAsp in Type 2 Diabetes about?

The Soli-D randomized controlled trial compared the efficacy and safety of iGlarLixi and IDegAsp in Chinese adults with type 2 diabetes inadequately controlled by oral medications. Results showed that iGlarLixi provided superior HbA1c reduction, decreased body weight, and lower hypoglycemia rates compared to IDegAsp after 24 weeks of treatment. This study highlights iGlarLixi as a beneficial alternative for managing type 2 diabetes in this population.

Author

pınar güven

Language

EN